Julio Francisco Jiménez-Bonilla
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Julio Francisco Jiménez-Bonilla has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Ignacio Banzo
Servicio de Medicina Nuclear, Hospital Universitario «Marqués de Valdecilla», Grupo de Imagen Molecular IDIVAL, Universidad de Cantabria, Santander, Spain
13 shared publicationsIsabel Martínez-Rodríguez
7 shared publicationsRemedios Quirce
7 shared publicationsJosé M. Carril
4 shared publicationsJ.M. Carril Carril
Servicio de Medicina Nuclear, Hospital «Marqués de Valdecilla», Universidad de Cantabria, Santander, Spain
3 shared publicationsJosé Manuel Carril
3 shared publications
Latest Publications
- 5 February 2019
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 152 (6) , e33
Reply
- 6 December 2018
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 151 (11) , 464-465
Usefulness of 18F-FDG-PET/CT imaging in a patient with neurosarcoidosis
- 6 December 2018
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 151 (11) , 464-465
Usefulness of 18F-FDG-PET/CT imaging in a patient with neurosarcoidosis
- 1 December 2018
- Published by Elsevier in Medicina Clinica
- Vol. 151 (11) , 464-465
Usefulness of 18F-FDG-PET/CT imaging in a patient with neurosarcoidosis
- 1 December 2018
- Published by Elsevier in Medicina Clinica
- Vol. 151 (11) , 464-465
Usefulness of 18F-FDG-PET/CT imaging in a patient with neurosarcoidosis
- 15 October 2018
- Published by Elsevier in Medicina Clinica
- Vol. 152 (6) , e33
Réplica
- 23 May 2018
- Published by Elsevier in Medicina Clinica
- Vol. 150 (10) , 387-389
Non-oncological applications of PET/CT
- 23 May 2018
- Published by Elsevier in Medicina Clinica
- Vol. 150 (10) , 387-389
Non-oncological applications of PET/CT
- 4 April 2018
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 150 (10) , 387-389
Non-oncological applications of PET/CT
- 4 April 2018
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 150 (10) , 387-389
Non-oncological applications of PET/CT
- 1 November 2016
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 37 (11) , 1189-1196
Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients
Objective Amyloid imaging clinically is usually reported as positive or negative, and the role of amyloid topography has not been studied before. To evaluate in a clinical setting the regional distribution patterns of 11C-Pittsburgh compound B (11C-PIB) and the fluorine-18-fluorodeoxyglucose (18F-FDG) uptake in patients with mild cognitive impairment (MCI), we designed this study. Methods We studied 81 consecutive MCI patients, 64 amnestic (A-MCI) and 17 nonamnestic (NA-MCI) by 11C-PIB and 18F-FDG PET/computed tomography, by visual analysis. PIB retention was classified according to the regional distribution into the following patterns: A (frontal, lateral temporal, basal ganglia and anterior cingulate) and B (global retention). 18F-FDG images were considered positive only if temporoparietal hypometabolism consistent with Alzheimer’s disease was observed. Results In 42 of the 64 A-MCI, 11C-PIB was positive. Twelve of the 42 positive A-MCI showed an A-pattern, all 18F-FDG negative, and 30 a B-pattern, 10 18F-FDG positive and 20 18F-FDG negative. Of the 17 NA-MCI, 11C-PIB was positive in three and 18F-FDG was positive in one. The different proportion of 11C-PIB positivity in A-MCI and NA-MCI was highly significant (P11C-PIB patterns were observed in MCI patients and for the A-pattern, glucose hypometabolism consistent with Alzheimer’s disease is highly unlikely. These findings may contribute towards a better selection of patients for future potential treatments and also to optimize the use of 18F-FDG-PET/CT.
- 1 November 2016
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 37 (11) , 1189-1196
Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients
Objective Amyloid imaging clinically is usually reported as positive or negative, and the role of amyloid topography has not been studied before. To evaluate in a clinical setting the regional distribution patterns of 11C-Pittsburgh compound B (11C-PIB) and the fluorine-18-fluorodeoxyglucose (18F-FDG) uptake in patients with mild cognitive impairment (MCI), we designed this study. Methods We studied 81 consecutive MCI patients, 64 amnestic (A-MCI) and 17 nonamnestic (NA-MCI) by 11C-PIB and 18F-FDG PET/computed tomography, by visual analysis. PIB retention was classified according to the regional distribution into the following patterns: A (frontal, lateral temporal, basal ganglia and anterior cingulate) and B (global retention). 18F-FDG images were considered positive only if temporoparietal hypometabolism consistent with Alzheimer’s disease was observed. Results In 42 of the 64 A-MCI, 11C-PIB was positive. Twelve of the 42 positive A-MCI showed an A-pattern, all 18F-FDG negative, and 30 a B-pattern, 10 18F-FDG positive and 20 18F-FDG negative. Of the 17 NA-MCI, 11C-PIB was positive in three and 18F-FDG was positive in one. The different proportion of 11C-PIB positivity in A-MCI and NA-MCI was highly significant (P11C-PIB patterns were observed in MCI patients and for the A-pattern, glucose hypometabolism consistent with Alzheimer’s disease is highly unlikely. These findings may contribute towards a better selection of patients for future potential treatments and also to optimize the use of 18F-FDG-PET/CT.
- Open Access
- 30 September 2016
- Published by MDPI AG in Diagnostics
- Vol. 6 (4) , 36
The Role of PET/CT Molecular Imaging in the Diagnosis of Recurrence and Surveillance of Patients Treated for Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide and its prognosis remains poor. Molecular imaging with 18F-FDG PET/CT can metabolically characterize the nature of lesions as benign or malignant, allowing a better staging at the diagnosis of this kind of patient. This advantage can also be applied in the re-staging due to the suspicion of recurrent disease. Many patients have a recurrence of the disease, including surgically treated patients. In the current context, with new personalized oncological treatments, the surveillance for recurrence and its accurate diagnosis are crucial to improve their survival. In this paper, we revise the current knowledge about the clinical and molecular factors related to the recurrent disease. In the context of new, promising, available personalized treatments, the role of molecular imaging with PET/CT and 18F-FDG and non-18F-FDG radiotracers in the follow-up of NSCLC-treated patients is especially attractive and interesting.
- 30 September 2016
- Published by MDPI AG in Diagnostics
- Vol. 6 (4) , 36
Open AccessThe Role of PET/CT Molecular Imaging in the Diagnosis of Recurrence and Surveillance of Patients Treated for Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide and its prognosis remains poor. Molecular imaging with 18F-FDG PET/CT can metabolically characterize the nature of lesions as benign or malignant, allowing a better staging at the diagnosis of this kind of patient. This advantage can also be applied in the re-staging due to the suspicion of recurrent disease. Many patients have a recurrence of the disease, including surgically treated patients. In the current context, with new personalized oncological treatments, the surveillance for recurrence and its accurate diagnosis are crucial to improve their survival. In this paper, we revise the current knowledge about the clinical and molecular factors related to the recurrent disease. In the context of new, promising, available personalized treatments, the role of molecular imaging with PET/CT and 18F-FDG and non-18F-FDG radiotracers in the follow-up of NSCLC-treated patients is especially attractive and interesting.
- 1 January 2016
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 41 (1) , e18-e23
Amyloid Imaging With 11C-PIB in Patients With Cognitive Impairment in a Clinical Setting
Purpose The aim of this study was to evaluate amyloid imaging with 11C-PIB PET/CT in the study of cognitive impairment in a clinical setting. Patients and Methods The study included 64 patients, with a mean age of 65 years, classified as subjective memory complaints (SMCs; n = 8), nonamnestic mild cognitive impairment (NA-MCI; n = 10), amnestic MCI (A-MCI; n = 19), prodromal Alzheimer disease (AD; n = 12), suspicion of frontotemporal dementia (n = 8), Lewy bodies dementia (DLB; n = 2), and cortical degeneration (CD; n = 5). Ten healthy controls (HCs), with a mean age of 59 years, were also included. 11C-PIB was acquired 60 minutes after IV injection of 555 MBq 11C-PIB. A visual and semiquantitative analysis was performed. Results In HC, 11C-PIB was negative in 9 and positive in 1. Of the 64 patients, 11C-PIB was negative in 27 (42%) and positive in 37 (58%). 11C-PIB was positive in 3 of 8 SMC, in none of 10 NA-MCI, in 14 of 19 A-MCI, in 10 of 12 prodromal AD, in 3 of 8 frontotemporal dementia, and in the 2 and 5 DLB and CD patients. The semiquantitative results in terms of mean global SUV ratio were 1.13 for HC, 1.36 for SMC, 1.07 for NA-MCI, 2.01 for A-MCI, 2.37 for prodromal AD, 2.75 for DLB, and 2.44 for CD. Conclusions In a clinical setting, 11C-PIB scan had a relevant contribution on patients with cognitive impairment, excluding AD in a high proportion of MCI patients and differentiating AD from other dementias. In A-MCI, 11C-PIB revealed β-amyloid deposit in 74%, whereas it was negative in all NA-MCI patients.
- 1 January 2016
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 41 (1) , e18-e23
Amyloid Imaging With 11C-PIB in Patients With Cognitive Impairment in a Clinical Setting
Purpose The aim of this study was to evaluate amyloid imaging with 11C-PIB PET/CT in the study of cognitive impairment in a clinical setting. Patients and Methods The study included 64 patients, with a mean age of 65 years, classified as subjective memory complaints (SMCs; n = 8), nonamnestic mild cognitive impairment (NA-MCI; n = 10), amnestic MCI (A-MCI; n = 19), prodromal Alzheimer disease (AD; n = 12), suspicion of frontotemporal dementia (n = 8), Lewy bodies dementia (DLB; n = 2), and cortical degeneration (CD; n = 5). Ten healthy controls (HCs), with a mean age of 59 years, were also included. 11C-PIB was acquired 60 minutes after IV injection of 555 MBq 11C-PIB. A visual and semiquantitative analysis was performed. Results In HC, 11C-PIB was negative in 9 and positive in 1. Of the 64 patients, 11C-PIB was negative in 27 (42%) and positive in 37 (58%). 11C-PIB was positive in 3 of 8 SMC, in none of 10 NA-MCI, in 14 of 19 A-MCI, in 10 of 12 prodromal AD, in 3 of 8 frontotemporal dementia, and in the 2 and 5 DLB and CD patients. The semiquantitative results in terms of mean global SUV ratio were 1.13 for HC, 1.36 for SMC, 1.07 for NA-MCI, 2.01 for A-MCI, 2.37 for prodromal AD, 2.75 for DLB, and 2.44 for CD. Conclusions In a clinical setting, 11C-PIB scan had a relevant contribution on patients with cognitive impairment, excluding AD in a high proportion of MCI patients and differentiating AD from other dementias. In A-MCI, 11C-PIB revealed β-amyloid deposit in 74%, whereas it was negative in all NA-MCI patients.